BetterLife Announces Closing of a Private Placement

By adminJuly 5, 2024Embryonic Stem Cells

VANCOUVER, British Columbia, July 02, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, announced that it has closed a non-brokered private placement, previously announced on June 13, 2024, pursuant to which the Company issued 1,750,000 units (“Units”) at a price of $0.10 per Unit for aggregate gross proceeds of $175,000 (the “Offering”). Each Unit is comprised of one common share and one full warrant. Each warrant entitles the holder thereof to acquire one common share at an exercise price of $0.13 at any time up to 24 months from the closing of the Offering. The Units sold pursuant to the Offering will be subject to a four month hold period pursuant to applicable Canadian securities laws.

Original post:
BetterLife Announces Closing of a Private Placement

Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD

By adminJuly 5, 2024Embryonic Stem Cells

First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life

See the original post:
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD

Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD

By adminJuly 5, 2024Embryonic Stem Cells

Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD

More:
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD

Pentixapharm Acquires Target Discovery Business of Glycotope

By adminJuly 5, 2024Embryonic Stem Cells

WÜRZBURG, Germany and BERLIN, July 03, 2024 (GLOBE NEWSWIRE) -- Pentixapharm AG, a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals against a range of malignancies, has announced the execution of an agreement, effective July 1st, to acquire the target discovery business of Berlin-based Glycotope GmbH.

Read the original here:
Pentixapharm Acquires Target Discovery Business of Glycotope

Pneumagen Highlights Broad-Spectrum Antiviral Activity of First-in-Class Intranasal Drug Neumifil in New Publication

By adminJuly 5, 2024Embryonic Stem Cells

St Andrews, UK – 3 July 2024 - Pneumagen, a clinical stage biotech company developing Neumifil (HEX17), a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs), announces the publication of new preclinical data evaluating Neumifil in a wide range of viral disease models. These preclinical data are published in the peer-reviewed journal, Antiviral Research in a paper entitled, “HEX17(Neumifil): An intranasal respiratory biotherapeutic with broad-acting antiviral activity,” and confirm the potential of Neumifil as a first in class protein-based antiviral prophylactic for respiratory viral infections. The article can be accessed online at https://doi.org/10.1016/j.antiviral.2024.105945.

Read more from the original source:
Pneumagen Highlights Broad-Spectrum Antiviral Activity of First-in-Class Intranasal Drug Neumifil in New Publication

Olon Group Announces the Acquisition of GTP Bioways Group

By adminJuly 5, 2024Embryonic Stem Cells

MILAN, July 03, 2024 (GLOBE NEWSWIRE) -- GTP Bioways Group is a French company operating as Biotech CDMO (Contract Developing and Manufacturing Organisation), specialising in R&D Services, process development and production of mAbs, enzymes, proteins, nanodrugs, ADCs and F&F. GTP Bioways Group, with multiple locations across France, specializes in delivering comprehensive services to biopharmaceutical companies. From preclinical development to commercial stages, the group focuses on utilizing cutting-edge technologies to advance innovative therapies.

See the rest here:
Olon Group Announces the Acquisition of GTP Bioways Group

Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China

By adminJuly 5, 2024Embryonic Stem Cells

Planegg/Martinsried, July 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued a patent by the Chinese Patent Office protecting its T cell receptor (TCR) targeting NY-ESO-1 (New York esophageal squamous cell carcinoma 1) and LAGE 1a (L Antigen Family Member-1a), both being well-recognized and validated cancer-testis antigens, expressed in multiple tumor types.

More:
Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China

Skye Bioscience Appoints Dr. Karen Smith to Board of Directors

By adminJuly 5, 2024Embryonic Stem Cells

Seasoned industry veteran adds significant global biotech and biopharma experience to Skye’s Board of Directors Seasoned industry veteran adds significant global biotech and biopharma experience to Skye’s Board of Directors

Read the original:
Skye Bioscience Appoints Dr. Karen Smith to Board of Directors

CorMedix Inc. Announces Outpatient Availability of DefenCath

By adminJuly 5, 2024Embryonic Stem Cells

BERKELEY HEIGHTS, N.J., July 03, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has commenced commercialization of DefenCath® (taurolidine and heparin) to outpatient dialysis centers and vascular access clinics where patients receive outpatient dialysis and catheter placement services. The outpatient launch coincides with the effective date of July 1st for outpatient reimbursement of DefenCath as directed by the Center for Medicare & Medicaid Services (CMS).

Go here to see the original:
CorMedix Inc. Announces Outpatient Availability of DefenCath

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

By adminJuly 5, 2024Embryonic Stem Cells

Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need

Originally posted here:
Apollomics Announces Updated Strategic Focus and Leadership Team Changes